MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/mat.0000000000001712

Медицинская библиотека · ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2022

Surgically Implanted Impella Device for Patients on Impella CP Support Experiencing Refractory Hemolysis.

Salas de Armas Ismael, Bergeron Amanda, Bhardwaj Anju, Patarroyo Maria, Akay Mehmet H, Al Rameni Dina, Nascimbene Angelo, Patel Manish K, Patel Jayeshkumar, Marcano Juan, Kar Biswajit, Gregoric Igor D

Клинический случайСтатьяПеревод в очереди

Аннотация

The Impella CP (Abiomed Inc., Danvers, MA) is widely used in cardiac catheterization laboratories for patients presenting with cardiogenic shock, but it is also known to cause significant hemolysis. The risk of hemolysis can be reduced by properly positioning the device, ensuring an adequate volume status, and using full anticoagulation strategies; however, in some cases hemolysis persists. We present a case series of eight patients that were diagnosed with cardiogenic shock, underwent Impella CP placement, and then suffered from refractory hemolysis which was treated by upgrading the Impella device to the 5.0 or 5.5 version. Fifty percent (4/8) of the patients in this series were already receiving continuous renal replacement therapy, and the levels of plasma free hemoglobin (pFHb) and lactate dehydrogenase continued to increase after the implantation of the Impella CP. The median time between Impella CP placement and the diagnosis of refractory hemolysis was 16.5 hours (interquartile range [IQR], 8.0-26.0). The median time between the diagnosis of hemolysis to Impella upgrade was 6.0 hours (IQR, 4.0-7.0). A total of 87.5% (7/8) of patients experienced a drop in pFHb to below 40 mg/dl at 72 hours post-Impella upgrade, and they were discharged without any further need of dialysis. One patient expired due to irreversible multiple organ failure. We propose that early identification of hemolysis by close monitoring of pFHb and upgrading to the Impella 5.5 reduces hemolysis, prevents further kidney damage, and significantly improves clinical outcomes.

Для цитирования: Salas de Armas Ismael, Bergeron Amanda, Bhardwaj Anju, Patarroyo Maria, Akay Mehmet H, Al Rameni Dina, Nascimbene Angelo, Patel Manish K, Patel Jayeshkumar, Marcano Juan, Kar Biswajit, Gregoric Igor D. Surgically Implanted Impella Device for Patients on Impella CP Support Experiencing Refractory Hemolysis.. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2022. DOI: 10.1097/mat.0000000000001712.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.